OCS Oculis Holding AG IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1953530 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 57.09M | 52.08M | 29.25M | 22.22M | 9.57M |
| SG&A expense | 25.79M | 21.81M | 17.49M | 11.06M | 4.62M |
| Operating income | -81.67M | -73.20M | -80.71M | -32.38M | -13.23M |
| Interest expense | 833,000 | 639,000 | 1.31M | 6.44M | 5.12M |
| Pretax income | -99.14M | -85.94M | -88.69M | -38.64M | -18.52M |
| Income tax | -186,000 | -160,000 | 107,000 | 55,000 | 27,000 |
| Net income | -98.96M | -85.78M | -88.80M | -38.70M | -18.55M |
| EPS (basic) | -1.89 | -2.12 | -2.97 | -11.32 | -5.84 |
| EPS (diluted) | -1.89 | -2.12 | -2.97 | -11.32 | -5.84 |
| Weighted avg. shares (diluted) | 52.24M | 40.41M | 29.90M | 2.99M | 2.78M |
| Banking | |||||
| Net interest income | — | — | — | 126,000 | 21,000 |
| Balance sheet | |||||
| Cash & equivalents | 81.33M | 27.71M | 38.33M | 19.79M | 46.28M |
| Current assets | 218.89M | 104.90M | 101.02M | 23.66M | 47.98M |
| PP&E, netmay include right-of-use assets (IFRS) | 534,000 | 385,000 | 288,000 | 365,000 | 431,000 |
| Intangibles | 13.29M | 13.29M | 12.21M | 12.21M | 8.72M |
| Total assets | 235.96M | 120.35M | 114.35M | 37.06M | 58.04M |
| Current liabilities | 36.75M | 44.23M | 19.09M | 12.02M | 4.06M |
| Total liabilities | 39.89M | 46.97M | 20.62M | 135.05M | 119.00M |
| Shareholders' equity | 196.07M | 73.38M | 93.73M | -97.99M | -60.95M |
| Shares outstanding | — | — | — | 3.41M | — |
| Cash flow statement | |||||
| Operating cash flow | -66.30M | -48.92M | -55.04M | -25.07M | -13.82M |
| Capital expenditure | 301,000 | 230,000 | 48,000 | 65,000 | 28,000 |
| Free cash flow | -66.61M | -49.15M | -55.09M | -25.14M | -13.85M |
| Investing cash flow | -60.93M | -16.08M | -52.97M | -3.55M | -28,000 |
| Financing cash flow | 186.92M | 53.98M | 129.63M | 1.71M | 55.19M |
| Stock-based compensation | 16.04M | 9.78M | 3.61M | 804,000 | 328,000 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.